肝癌单抗放射免疫治疗后的人抗鼠抗体检测

HUMAN ANTI-MOUSE ANTIBODY DETECTION IN HEPATOCELLULAR CARCINOMA PATIENTS AFTER RADIOIMMUMOTHERAPY WITH MOUSE MONOCLONAL ANTIBODY

本文报告经（１３１）Ｉ－抗人肝癌单克隆抗体肝动脉内治疗后，肝癌病人血中抗鼠抗体（ＨＡＭＡ）的检测结果。以间接酶联免疫吸附法（ＥＬＩＳＡ）检测，给药后ＨＡＭＡ阳性率为３４．４％（１１／３２），阳性高峰出现在给药后的２～３周内。１１例接受单抗总剂量小于１０ｍｇ者，ＨＡＭＡ阳性率仅９．１％（１／１１），而总剂量大于１０ｍｇ者，ＨＡＭＡ阳性率达４７．６％（１０／２１）。ＨＡＭＡ阳性者的Ｔ淋巴细胞亚群比例与正常组无明显差别，而ＨＡＭＡ阴性者其Ｔ淋巴细胞亚群比例与正常组及ＨＡＭＡ阳性组比较有显著差别，表现为ＣＤ亚群低于阳性组及正常组，ＣＤ亚群高于正常组，ＣＤ／ＣＤ比例显著低于阳性组和正常组。结果提示：ＨＡＭＡ的产生与外源性单抗剂量以及患者的免疫功能状态密切相关。

Results of human anti-mouse antibody(HAMA) detection in sera from hepatocellular carcinoma(HCC)patients after radiolabeled mouse monoclonal antibody Hepama-I(McAb)were reported. By using ELISA, HAMA was detected in 34. 4%(11/32) of HCC patients, with the peak titre in the second and third weeks after intrahepatic arterial injection.HAMA was detected in only 9. 1%(1/11)of patients who received total dose of McAb lower than 10mg, whereas it was 47. 6% (10/21)in patients who received higher than 10 mg(P<0. 05).The proportion of CD T lymphocyte subset in HAMA negative patients was lower than that of HAMA positive and control groups, while that of CD T lymphocyte subset was higher than control group. The ratio of CD4 : CD8 in the HAMA negative patients was significantly lower than that in both HAMA positive and control groups. No difference of T lymphocyte subsets was found between HAMA positive and control groups. These results suggested that HAMA response was colosely related to the dosage of McAb injected and the immune status of patients.